Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
Prospective Study on Anti-Amyloid-β Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease Coverage of Evidence Development (The Anti-Aβ mAb CED Study)
Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
8,680 participants
Jul 6, 2023
OBSERVATIONAL
Conditions
Summary
The Anti-Aβ mAb CED Study is a prospective, longitudinal coverage with evidence development (CED) study using clinical data, patient assessments, and administrative claims data of the Medicare population, conducted in accordance to the National Coverage Determination (NCD) on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (AD).
Eligibility
Inclusion Criteria1
- Medicare patients with a clinical diagnosis of mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia, both with confirmed presence of amyloid beta pathology consistent with AD.
Exclusion Criteria1
- none
Interventions
FDA approved monoclonal antibodies directed against amyloid for the treatment of AD
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06058234